Reading a press release from Pfizer where they are paying Opko Health $295 million to gain global development and commercial rights to Opko's late-stage, long-acting human growth hormone.
The compound is hGH-CTP and is currently in Phase 3 clinical trials for adults.
The compound is hGH-CTP and is currently in Phase 3 clinical trials for adults.